Ekso Bionics shareholders approve all proposals at 2024 annual meeting

EKSO BIONICS HOLDINGS, INC.

All five director nominees elected: Scott Davis, Mary Ann Cloyd, Corinna Lathan, Charles Li, Deborah Lafer Scher.
Equity incentive plan extended to April 2034; authorized shares increased to 4,724,286 (1M increase).
Advisory say-on-pay approved: 6,303,399 for, 631,663 against, 124,065 abstained.
Annual frequency for future advisory votes selected: 6,840,255 for 1 year.
WithumSmith+Brown ratified as auditor for FY2024: 11,245,624 for, 153,991 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.